American volunteers test the vaccine
IRBM / Press Review / American volunteers test the vaccine
While the novel coronavirus Covid-19 keeps spreading, and the first clinical trial has begun in the Kaiser Permanente Washington Research Institute of Seattle, many companies are working on a vaccine, and Italy is at the forefront. We are talking about a joint venture between the Jenner Institute of the Oxford University and Advent Srl, the GMP-certified Contract Development and Manufacturing Organization of IRBM Group, located in Pomezia, Rome. The key to success of the Italian "candidate" could be the expertise of the two partners. The Jenner Institute is expert in surface antigens –called "Spike", which are being largely studied in the coronavirus field. On the other hand Advent has already used an adenovirus platform widely. Pietro Di Lorenzo, President and CEO of IRBM, CEO of Advent and CNCCS, explains why the candidate vaccine works like a "chimera" for the coronavirus.
Article by Francesca Cerati and Federico Mereta published on Il Sole 24 Ore Salute – 17/03/2020
IRBM EDITORIAL
Interview with Piero Di Lorenzo «The Oxford vaccine has an efficacy of 90%»
Source: Il Messaggero
Interview with Matteo Liguori. Research needs time
Source: Fortune Italia
"The vaccine activates many antibodies". Steps forward thanks to the tests on elderly people
Source: La Stampa
previous post: A light at the end of the tunnel. The number of deaths is increasing, but the vaccine is about to arrive
next post: Into the guys' lab "Our sleepless nights to save the world"